BNP 和 NTproBNP 市场 - 全球产业规模、份额、趋势、机会和预测，按类型、检测地点、应用、地区和竞争格局划分，2020-2030 年预测

2024年全球BNP和NT-proBNP市场规模为19.2亿美元，预计2030年将以7.15%的复合年增长率成长至29.1亿美元。脑钠肽（BNP）和N端脑钠肽前体（NT-proBNP）是心肌细胞在心室扩张或压力负荷过重时分泌的心臟生物标记物，是心臟衰竭和其他心血管疾病的重要诊断指标。全球心血管疾病发生率的上升和老年人口的不断增长（老年人尤其容易患心臟疾病）是推动这些诊断检测市场成长的主要因素。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球 BNP 与 NTproBNP 市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依类型（脑钠肽、NT-proBNP（N 端脑钠肽前驱物））
  • 依检测地点（即时检测、实验室检测）
  • 依应用领域（心肌梗塞、充血性心臟衰竭、急性冠状动脉综合症（ACS）、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美BNP和NTproBNP市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲 BNP 和 NTproBNP 市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区 BNP 和 NTproBNP 市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲 BNP 和 NTproBNP 市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美 BNP 与 NTproBNP 市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球 BNP 和 NTproBNP 市场：SWOT 分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Specim, Spectral Imaging Ltd
• Gentian Diagnostics ASA
• Siemens AG
• PerkinElmer Inc
• Biomerieux SA
• Quidel Corporation
• Bio-Rad Laboratories, Inc.
• F. Hoffman-La Roche Ltd
• BHR Pharmaceuticals Ltd.
• Xiamen Biotime Biotechnology Co., Ltd.

第十六章：策略建议

第17章调查会社について・免责事项

The Global BNP And NTproBNP Market, valued at USD 1.92 Billion in 2024, is projected to experience a CAGR of 7.15% to reach USD 2.91 Billion by 2030. Brain Natriuretic Peptide (BNP) and N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) are cardiac biomarkers secreted by cardiomyocytes in response to ventricular stretch or pressure overload, serving as critical diagnostic indicators for heart failure and other cardiovascular conditions. The market for these diagnostic assays is substantially driven by the increasing global incidence of cardiovascular diseases and the expanding geriatric population, which is particularly susceptible to cardiac ailments.

Key Market Drivers

The growth of the Global BNP and NTproBNP Market is significantly influenced by the escalating prevalence of cardiovascular diseases and the expanding geriatric population increasingly susceptible to heart conditions. The rising incidence of cardiovascular diseases necessitates widespread diagnostic and prognostic tools like BNP and NTproBNP assays for early detection and disease management. According to the World Health Organization, in 2022, an estimated 19.8 million people died from cardiovascular diseases, highlighting the profound global health burden these conditions impose. Concurrently, the increasing longevity of populations worldwide contributes to a higher prevalence of age-related cardiac ailments. This demographic shift directly fuels demand for cardiac biomarkers.

Key Market Challenges

The inherent limited specificity of Brain Natriuretic Peptide and N-terminal pro-B-type Natriuretic Peptide tests significantly impedes market expansion. Elevated levels of these biomarkers can arise from various non-cardiac conditions, such as renal failure and pulmonary embolism, potentially leading to false-positive diagnoses and complicating clinical interpretation. This lack of singular diagnostic clarity diminishes confidence in the tests as standalone indicators for heart failure.

Key Market Trends

The expanding integration of point-of-care (PoC) testing represents a significant trend in the global BNP and NTproBNP market by decentralizing diagnostic capabilities and enabling rapid clinical decisions. PoC devices provide immediate results, crucial for managing acute cardiac events and enhancing patient throughput in emergency settings. This trend reflects a broader move towards more accessible and efficient diagnostic pathways. For instance, the American College of Cardiology in a journal scan from August 2024, highlighted a 2-hour strategy for point-of-care high-sensitivity cardiac troponin I testing in suspected acute myocardial infarction, underscoring the drive for expedited cardiac biomarker assessment.

Key Market Players

• Specim, Spectral Imaging Ltd
• Gentian Diagnostics ASA
• Siemens AG
• PerkinElmer Inc
• Biomerieux SA
• Quidel Corporation
• Bio-Rad Laboratories, Inc.
• F. Hoffman-La Roche Ltd
• BHR Pharmaceuticals Ltd.
• Xiamen Biotime Biotechnology Co., Ltd.

Report Scope:

In this report, the Global BNP And NTproBNP Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

BNP And NTproBNP Market, By Type:

• Brain Natriuretic Peptide
• NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide)

BNP And NTproBNP Market, By Location of Testing:

• Point Of Care Testing
• Laboratory Testing

BNP And NTproBNP Market, By Application:

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome (ACS)
• Others

BNP And NTproBNP Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global BNP And NTproBNP Market.

Available Customizations:

Global BNP And NTproBNP Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global BNP And NTproBNP Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Brain Natriuretic Peptide, NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide))
  • 5.2.2. By Location of Testing (Point Of Care Testing, Laboratory Testing)
  • 5.2.3. By Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America BNP And NTproBNP Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Location of Testing
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States BNP And NTproBNP Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Location of Testing
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada BNP And NTproBNP Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Location of Testing
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico BNP And NTproBNP Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Location of Testing
      • 6.3.3.2.3. By Application

7. Europe BNP And NTproBNP Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Location of Testing
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany BNP And NTproBNP Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Location of Testing
      • 7.3.1.2.3. By Application
  • 7.3.2. France BNP And NTproBNP Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Location of Testing
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom BNP And NTproBNP Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Location of Testing
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy BNP And NTproBNP Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Location of Testing
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain BNP And NTproBNP Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Location of Testing
      • 7.3.5.2.3. By Application

8. Asia Pacific BNP And NTproBNP Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Location of Testing
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China BNP And NTproBNP Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Location of Testing
      • 8.3.1.2.3. By Application
  • 8.3.2. India BNP And NTproBNP Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Location of Testing
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan BNP And NTproBNP Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Location of Testing
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea BNP And NTproBNP Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Location of Testing
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia BNP And NTproBNP Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Location of Testing
      • 8.3.5.2.3. By Application

9. Middle East & Africa BNP And NTproBNP Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Location of Testing
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia BNP And NTproBNP Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Location of Testing
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE BNP And NTproBNP Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Location of Testing
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa BNP And NTproBNP Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Location of Testing
      • 9.3.3.2.3. By Application

10. South America BNP And NTproBNP Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Location of Testing
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil BNP And NTproBNP Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Location of Testing
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia BNP And NTproBNP Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Location of Testing
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina BNP And NTproBNP Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Location of Testing
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global BNP And NTproBNP Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Specim, Spectral Imaging Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Gentian Diagnostics ASA
• 15.3. Siemens AG
• 15.4. PerkinElmer Inc
• 15.5. Biomerieux SA
• 15.6. Quidel Corporation
• 15.7. Bio-Rad Laboratories, Inc.
• 15.8. F. Hoffman-La Roche Ltd
• 15.9. BHR Pharmaceuticals Ltd.
• 15.10. Xiamen Biotime Biotechnology Co., Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer